RNA治療薬の世界市場：タイプ別、製品別、適応症別、エンドユーザー別、地域別、機会、予測、2017年～2031年

世界のRNA治療薬の市場規模は、2023年に101億米ドルと評価され、2031年には273億3,000万米ドルに達すると予測されており、2024年から2031年までの予測期間のCAGRは13.25%になるとみられています。世界のRNA治療薬市場に影響を与える要因としては、RNA技術の進歩、研究資金の増強、慢性疾患の罹患率の上昇、個別化医療の需要、以前は不治の病であった病態の治療におけるRNAベースの薬剤の有効性、規制当局の支援や製薬企業間の提携の大きな影響などが挙げられ、これらすべてが市場拡大に寄与しています。

複数の極めて重要な要因が世界のRNA治療薬市場に大きな影響を与えており、それぞれが市場の拡大と進展に重要な役割を果たしています。主に、RNA技術の継続的な進歩が市場成長の礎となっています。メッセンジャーRNA（mRNA）、低分子干渉RNA（siRNA）、アンチセンスオリゴヌクレオチド、および関連技術における絶え間ない技術革新は、治療アプローチの精度と有効性を一貫して強化しています。これらの進歩は、薬物の安定性、標的の正確さ、最適化されたデリバリー方法に関する歴史的課題に対処するものです。研究資金の増強は、もう一つの促進要因です。資金援助の急増は、RNAを中心とした先進的な研究を推進し、ブレークスルーを早め、発見を世界のRNA治療薬市場における実行可能な臨床応用に結びつける。資金援助の増加は、より深い探求を可能にし、イノベーションを促進し、RNA発見の実用的な治療への転換を促進します。

さらに、慢性疾患の増加により、効果的な治療法の必要性が高まっており、RNAベースの介入の適応性とシームレスに連携することで、世界のRNA治療薬市場を大きく牽引しています。RNA治療薬は、これまで克服できなかった病態に対処する有望な可能性を提供し、従来の薬物療法では不十分なシナリオに希望を与えます。個別化医療に対する需要が急増していることも、市場の拡大をさらに後押ししています。RNAベースの医薬品は、個々の遺伝子プロファイルを活用することで、患者の個別のニーズをより正確に満たすカスタマイズされた治療法を構築し、オーダーメイドのソリューションを提供します。さらに、規制当局の後押しや製薬企業間の提携の影響力は依然として極めて大きいです。有利な規制環境と戦略的パートナーシップは、研究開発・商業化を促進する環境を作り出し、最終的に世界のRNA治療薬市場の成長を後押しします。

当レポートでは、世界のRNA治療薬市場について調査し、市場の概要とともに、タイプ別、製品別、適応症別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のRNA治療薬市場の見通し、2017年～2031年

• 市場規模と予測
• タイプ別
• 製品別
• 適応症別
• エンドユーザー別
• 地域別
• 企業別市場シェア（%）、2023年

第5章 世界のRNA治療薬市場の見通し、地域別、2017年～2031年

• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第6章 市場マッピング、2023年

第7章 マクロ環境と産業構造

• 需給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要参入企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• BioNTech SE
• Moderna, Inc.
• Ionis Pharmaceuticals, Inc.
• Alnylam Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.
• Abogen Biosciences Co., Ltd
• Laronde, Inc.
• Sirnaomics, Inc.
• Deep Genomics Incorporated
• Nutcracker Therapeutics, Inc.
• GSK plc.
• Bristol-Myers Squibb Company

第14章 戦略的提言

第15章 お問合せと免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 3. Global RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 4. Global RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 5. Global RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 6. Global RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 7. Global RNA Therapeutics Market Share (%), By Region, 2017-2031F
• Figure 8. North America RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 9. North America RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 10. North America RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 11. North America RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 12. North America RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 13. North America RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 14. North America RNA Therapeutics Market Share (%), By Country, 2017-2031F
• Figure 15. United States RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 16. United States RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 17. United States RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 18. United States RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 19. United States RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 20. United States RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 21. Canada RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 22. Canada RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 23. Canada RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 24. Canada RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 25. Canada RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 26. Canada RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 27. Mexico RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 28. Mexico RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 29. Mexico RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 30. Mexico RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 31. Mexico RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 32. Mexico RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 33. Europe RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 34. Europe RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 35. Europe RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 36. Europe RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 37. Europe RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 38. Europe RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 39. Europe RNA Therapeutics Market Share (%), By Country, 2017-2031F
• Figure 40. Germany RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 41. Germany RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 42. Germany RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 43. Germany RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 44. Germany RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 45. Germany RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 46. France RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 47. France RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 48. France RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 49. France RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 50. France RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 51. France RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 52. Italy RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Italy RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 54. Italy RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 55. Italy RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 56. Italy RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 57. Italy RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 58. United Kingdom RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 59. United Kingdom RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 60. United Kingdom RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 61. United Kingdom RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 62. United Kingdom RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 63. United Kingdom RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 64. Russia RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 65. Russia RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 66. Russia RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 67. Russia RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 68. Russia RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 69. Russia RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 70. Netherlands RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 71. Netherlands RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 72. Netherlands RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 73. Netherlands RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 74. Netherlands RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 75. Netherlands RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 76. Spain RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 77. Spain RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 78. Spain RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 79. Spain RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 80. Spain RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 81. Spain RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 82. Turkey RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 83. Turkey RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 84. Turkey RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 85. Turkey RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 86. Turkey RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 87. Turkey RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 88. Poland RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 89. Poland RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 90. Poland RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 91. Poland RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 92. Poland RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 93. Poland RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 94. South America RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 95. South America RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 96. South America RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 97. South America RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 98. South America RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 99. South America RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 100. South America RNA Therapeutics Market Share (%), By Country, 2017-2031F
• Figure 101. Brazil RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 102. Brazil RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 103. Brazil RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 104. Brazil RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 105. Brazil RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 106. Brazil RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 107. Argentina RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 108. Argentina RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 109. Argentina RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 110. Argentina RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 111. Argentina RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 112. Argentina RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 113. Asia-Pacific RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 114. Asia-Pacific RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 115. Asia-Pacific RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 116. Asia-Pacific RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 117. Asia-Pacific RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 118. Asia-Pacific RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 119. Asia-Pacific RNA Therapeutics Market Share (%), By Country, 2017-2031F
• Figure 120. India RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 121. India RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 122. India RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 123. India RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 124. India RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 125. India RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 126. China RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 127. China RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 128. China RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 129. China RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 130. China RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 131. China RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 132. Japan RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 133. Japan RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 134. Japan RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 135. Japan RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 136. Japan RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 137. Japan RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 138. Australia RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 139. Australia RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 140. Australia RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 141. Australia RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 142. Australia RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 143. Australia RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 144. Vietnam RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 145. Vietnam RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 146. Vietnam RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 147. Vietnam RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 148. Vietnam RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 149. Vietnam RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 150. South Korea RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 151. South Korea RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 152. South Korea RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 153. South Korea RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 154. South Korea RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 155. South Korea RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 156. Indonesia RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 157. Indonesia RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 158. Indonesia RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 159. Indonesia RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 160. Indonesia RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 161. Indonesia RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 162. Philippines RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 163. Philippines RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 164. Philippines RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 165. Philippines RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 166. Philippines RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 167. Philippines RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 168. Middle East & Africa RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 169. Middle East & Africa RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 170. Middle East & Africa RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 171. Middle East & Africa RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 172. Middle East & Africa RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 173. Middle East & Africa RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 174. Middle East & Africa RNA Therapeutics Market Share (%), By Country, 2017-2031F
• Figure 175. Saudi Arabia RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 176. Saudi Arabia RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 177. Saudi Arabia RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 178. Saudi Arabia RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 179. Saudi Arabia RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 180. Saudi Arabia RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 181. UAE RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 182. UAE RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 183. UAE RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 184. UAE RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 185. UAE RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 186. UAE RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 187. South Africa RNA Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 188. South Africa RNA Therapeutics Market, By Volume, In Millions, 2017-2031F
• Figure 189. South Africa RNA Therapeutics Market Share (%), By Type, 2017-2031F
• Figure 190. South Africa RNA Therapeutics Market Share (%), By Product, 2017-2031F
• Figure 191. South Africa RNA Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 192. South Africa RNA Therapeutics Market Share (%), By End-user, 2017-2031F
• Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 194. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 195. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global RNA therapeutics market size was valued at USD 10.1 billion in 2023, which is expected to reach USD 27.33 billion in 2031, with a CAGR of 13.25% for the forecast period between 2024 and 2031F. Factors impacting the global RNA therapeutics market include progress in RNA technology, augmented research funding, heightened incidence of chronic diseases, demand for personalized medicine, effectiveness of RNA-based drugs in treating previously incurable conditions, and the substantial influence of regulatory support and collaborations among pharmaceutical firms, all contributing to market expansion.

Multiple pivotal factors significantly impact global RNA therapeutics market, each wielding a crucial role in its expansion and progression. Primarily, ongoing advancements in RNA technology serve as the cornerstone for market growth. Continuous innovations in messenger RNA (mRNA), small interfering RNA (siRNA), antisense oligonucleotides, and related techniques consistently bolster the precision and effectiveness of therapeutic approaches. These strides address historical challenges concerning drug stability, target accuracy, and optimized delivery methods. Augmented research funding represents another fundamental catalyst. The surge in financial support drives progressive RNA-centered studies, hastening breakthroughs and translating discoveries into viable clinical applications in the global RNA therapeutics market. The increased funding allows for deeper exploration, fostering innovation and expediting the conversion of RNA discoveries into practical therapies.

Additionally, the escalation in chronic diseases intensifies the need for effective treatments, aligning seamlessly with the adaptability of RNA-based interventions significantly driving the global RNA therapeutics market. RNA therapeutics offer promising potential in addressing previously insurmountable conditions, providing hope in scenarios where traditional medications fall short. The burgeoning demand for personalized medicine further fuels market expansion. RNA-based drugs present tailored solutions, leveraging individual genetic profiles to craft customized treatments that more precisely meet patients' distinct needs. Moreover, the significant influence of regulatory backing and collaborations among pharmaceutical firms remains pivotal. Favorable regulatory environments, coupled with strategic partnerships, create an environment conducive to research, development, and commercialization, ultimately propelling the growth of global RNA therapeutics market.

Progress in RNA Technology

Advancements in RNA technology are the primary catalyst driving the global RNA therapeutics market. These technological strides, encompass messenger RNA (mRNA), small interfering RNA (siRNA), antisense oligonucleotides, and other RNA-based methods, fueling the creation of inventive therapeutic remedies. They improve drug stability, target precision, and delivery systems, effectively tackling persistent challenges in precision medicine. Moreover, refined manufacturing processes and increased scalability fortify the practicality of RNA-based therapies, rendering them more attainable for large-scale manufacturing and commercial viability. The precision in gene expression manipulation via RNA interventions unlocks new avenues for addressing previously untreatable diseases, instilling hope in conditions lacking viable treatment options. The continuous evolution of RNA technology amplifies therapeutic potential and garners substantial investments, collaborations, and research endeavors, driving forward the growth and expansion of global RNA therapeutics market.

Augmented Research Funding

Increased funding for research plays a crucial role in propelling the global RNA therapeutics market. This boost in financial support infuses vital resources into pioneering RNA-centered studies, hastening breakthroughs and pushing discoveries toward practical clinical applications. It cultivates an environment ideal for experimenting, exploring, and validating various RNA-based therapeutic methods. Moreover, heightened funding draws in top-tier talent, sparks collaborative initiatives, and streamlines the transition of promising RNA technologies from lab settings to clinical trials. Consequently, this amplifies market growth potential and fosters the prospect of groundbreaking medical interventions.

For example, Flanders Innovation & Entrepreneurship (VLAIO) granted Flamingo Therapeutics a research grant of USD 1.9 million (EUR 1.7 million) in June 2023. The grant amounts to 60% of the project's total budget of USD 3.2 million (EUR 2.9 million). The award money will go towards expanding Flamingo Therapeutics' RNA-targeting oncology portfolio. It includes preclinical work on the company's long non-coding RNA (LncRNA) program targeting MALAT-1 and translational research for its lead clinical program, Danvatirsen, which is now in phase II trials for head and neck squamous cell carcinoma.

Government Initiatives

Governments worldwide are leading various initiatives that substantially elevate the global RNA therapeutics market. These initiatives encompass a range of strategies, including allocating research grants, establishing supportive regulatory frameworks, and fostering collaborations between public and private entities. Additionally, incentives like financial rewards, tax credits, and streamlined approval procedures reinforce progress in RNA-based advancements. Moreover, public health programs focusing on precision medicine and addressing previously untreatable conditions align with RNA therapeutics, stimulating increased government funding. The concerted effort fosters an environment conducive to research, development, and commercialization, significantly propelling notable growth in global RNA therapeutics market. For example, the Canada First Research Excellence Fund (CFREF) at Concordia University in Montreal would receive USD 1.4 billion in funding for 11 large-scale research activities, according to an announcement made a Minister of Innovation, Science, and Industry, in April 2023. The best programmes in their fields are given CFREF funding following a highly competitive process. To begin DNA to RNA, an Inclusive Canadian Approach to Genomic-based RNA treatments (D2R), a first-of-its-kind international research project focused on the creation and delivery of more inclusive genomic-based RNA treatments, McGill has been awarded a historic USD 165 million CFREF grant.

Treatment of Rare Genetic Disorders

RNA therapeutics significantly drive the expansion of global RNA therapeutics market by being instrumental in treating rare genetic disorders. These conditions, often resistant to conventional treatments, discover promise in RNA-based interventions capable of pinpointing precise genetic irregularities. As RNA therapies prove their efficacy in managing these once untreatable disorders, enthusiasm and investment escalate, fueling market growth. This specific application highlights RNA therapeutics' potential in meeting unaddressed medical demands, propelling both research initiatives and market progress. For instance, in October 2023, Novo Nordisk (NOVOb.CO) announced on Monday that FDA in the United States has approved its treatment for a rare kidney-affecting genetic disorder. It is approved for use in patients of nine years of age and older with a form of primary hyperoxaluria and generally intact kidney function to administer the once-monthly injection, which will be marketed under the brand name Rivfloza. RNA interference technology, or RNAi, is used in the therapy to assist lower urinary oxalate levels by silencing or neutralizing genes that contribute to illness.

Extensive use of RNAi Therapeutics

The global RNA therapeutics market experiences significant demand, particularly in RNA interference (RNAi) therapies. The interest arises from RNAi's distinct ability to target specific genes, impeding disease progression. RNAi's precision in controlling gene expression renders it an appealing option for treating diverse conditions like cancers, genetic disorders, and viral infections. As ongoing research continues to affirm RNAi's therapeutic potential and its effectiveness in both preclinical and clinical settings as the demand intensifies. The growing enthusiasm originates from RNAi's potential to address unmet medical needs, fostering a robust market propelled by the quest for innovative and precise therapeutic resolutions. For example, the industry-leading RNAi therapeutics company Alnylam Pharmaceuticals, Inc. announced in July 2023 that it has entered into a strategic agreement with Roche to develop and commercialize zilebesiran, the company's investigational RNAi therapeutic currently in Phase 2 development, for the treatment of hypertension. Through the agreement, Alnylam's P5x25 approach can move closer to its ambitious development ambition of upending the global paradigm of hypertension therapy.

Future Market Scenario

The forthcoming prospects of global RNA therapeutics market project significant expansion. The upsurge is driven by key elements such as ongoing progress in RNA technology. The fast-growing class of medications known as "RNA therapeutics" will enable personalized therapy, expedite the time it takes for solutions to reach the clinic, and end using the term "undruggable." Many more RNA medications are being developed, and the first ones have been approved. Other elements such as augmented investment in research and development, the escalating prevalence of chronic ailments, broader utilization of personalized medicine, and the potential of RNA-based remedies for formerly untreatable conditions will play a major role. Moreover, partnerships between pharmaceutical firms and favorable regulatory structures add impetus to this expected growth. The market's expansion pivots on the growing need for inventive therapeutic options, signaling a promising and resilient future for RNA-based interventions in tackling unmet medical challenges.

Key Players Landscape and Outlook

Major biotech companies worldwide are joining forces to establish an impactful alliance in the global RNA therapeutics market. The joint venture serves a dual purpose: advancing innovation and assuming regulatory roles. Together, these firms aim to combine their knowledge, resources, and research efforts to propel the development of innovative RNA-based therapies. Concurrently, their objective involves setting industry standards and guidelines to maintain quality and endorse the safety and effectiveness of RNA therapeutic solutions. The collaborative alliance signifies a crucial stride towards a cohesive strategy, driving progress and ensuring adherence to standards in the rapidly evolving domain of RNA therapeutics.

For instance, the Alliance for mRNA Medicines (AMM) was established in November 2023 by 31 biotechnology, biopharma, and life science businesses as well as academic institutions at the vanguard of mRNA and next generation encoding RNA medicines and vaccine development. Before legislative and regulatory agencies in North America, Europe, and Asia, AMM was the first and only scientific and policy organization exclusively dedicated to developing and advocating for global mRNA innovation and the sector's main policy objectives.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global RNA Therapeutics Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. Value
  • 4.1.2. Volume
• 4.2. By Type
  • 4.2.1. RNA Interference (RNAi) Therapeutics
  • 4.2.2. mRNA Therapeutics
  • 4.2.3. Antisense Oligonucleotide (ASO)Therapeutics
  • 4.2.4. Others
• 4.3. By Product
  • 4.3.1. Vaccines
  • 4.3.2. Drugs
• 4.4. By Indication
  • 4.4.1. Rare Genetic Diseases/Hereditary Diseases
  • 4.4.2. Infectious Diseases
  • 4.4.3. Others
• 4.5. By End-user
  • 4.5.1. Pharmaceutical and Biotechnology Companies
  • 4.5.2. Academic Research Centers
  • 4.5.3. Contract Research Organizations
  • 4.5.4. Others
• 4.6. By Region
  • 4.6.1. North America
  • 4.6.2. Europe
  • 4.6.3. South America
  • 4.6.4. Asia-Pacific
  • 4.6.5. Middle East and Africa
• 4.7. By Company Market Share (%), 2023

5. Global RNA Therapeutics Market Outlook, By Region, 2017-2031F

• 5.1. North America*
  • 5.1.1. Market Size & Forecast
    • 5.1.1.1. Value
    • 5.1.1.2. Volume
  • 5.1.2. By Type
    • 5.1.2.1. RNA Interference (RNAi) Therapeutics
    • 5.1.2.2. mRNA Therapeutics
    • 5.1.2.3. Antisense Oligonucleotide (ASO)Therapeutics
    • 5.1.2.4. Others
  • 5.1.3. By Product
    • 5.1.3.1. Vaccines
    • 5.1.3.2. Drugs
  • 5.1.4. By Indication
    • 5.1.4.1. Rare Genetic Diseases/Hereditary Diseases
    • 5.1.4.2. Infectious Diseases
    • 5.1.4.3. Others
  • 5.1.5. By End-user
    • 5.1.5.1. Pharmaceutical and Biotechnology Companies
    • 5.1.5.2. Academic Research Centers
    • 5.1.5.3. Contract Research Organizations
    • 5.1.5.4. Others
  • 5.1.6. United States*
    • 5.1.6.1. Market Size & Forecast
    • 5.1.6.1.1. Value
    • 5.1.6.1.2. Volume
    • 5.1.6.2. By Type
    • 5.1.6.2.1. RNA Interference (RNAi) Therapeutics
    • 5.1.6.2.2. mRNA Therapeutics
    • 5.1.6.2.3. Antisense Oligonucleotide (ASO)Therapeutics
    • 5.1.6.2.4. Others
    • 5.1.6.3. By Product
    • 5.1.6.3.1. Vaccines
    • 5.1.6.3.2. Drugs
    • 5.1.6.4. By Indication
    • 5.1.6.4.1. Rare Genetic Diseases/Hereditary Diseases
    • 5.1.6.4.2. Infectious Diseases
    • 5.1.6.4.3. Others
    • 5.1.6.5. By End-user
    • 5.1.6.5.1. Pharmaceutical and Biotechnology Companies
    • 5.1.6.5.2. Academic Research Centers
    • 5.1.6.5.3. Contract Research Organizations
    • 5.1.6.5.4. Others
  • 5.1.7. Canada
  • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

• 5.2. Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Russia
  • 5.2.6. Netherlands
  • 5.2.7. Spain
  • 5.2.8. Turkey
  • 5.2.9. Poland
• 5.3. South America
  • 5.3.1. Brazil
  • 5.3.2. Argentina
• 5.4. Asia-Pacific
  • 5.4.1. India
  • 5.4.2. China
  • 5.4.3. Japan
  • 5.4.4. Australia
  • 5.4.5. Vietnam
  • 5.4.6. South Korea
  • 5.4.7. Indonesia
  • 5.4.8. Philippines
• 5.5. Middle East & Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. UAE
  • 5.5.3. South Africa

6. Market Mapping, 2023

• 6.1. By Type
• 6.2. By Product
• 6.3. By Indication
• 6.4. By End-user
• 6.5. By Region

7. Macro Environment and Industry Structure

• 7.1. Supply Demand Analysis
• 7.2. Import Export Analysis
• 7.3. Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.5.1. Supplier Power
  • 7.5.2. Buyer Power
  • 7.5.3. Substitution Threat
  • 7.5.4. Threat from New Entrant
  • 7.5.5. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

• 9.1. Clinical Trials
• 9.2. Patent Landscape
• 9.3. Regulatory Approvals
• 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

• 10.1. Competition Matrix of Top Five Market Leaders
• 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4. SWOT Analysis (For Five Market Players)
• 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

• 13.1. BioNTech SE
  • 13.1.1. Company Details
  • 13.1.2. Key Management Personnel
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Key Market Focus & Geographical Presence
  • 13.1.6. Recent Developments
• 13.2. Moderna, Inc.
• 13.3. Ionis Pharmaceuticals, Inc.
• 13.4. Alnylam Pharmaceuticals, Inc.
• 13.5. Sarepta Therapeutics, Inc.
• 13.6. Abogen Biosciences Co., Ltd
• 13.7. Laronde, Inc.
• 13.8. Sirnaomics, Inc.
• 13.9. Deep Genomics Incorporated
• 13.10. Nutcracker Therapeutics, Inc.
• 13.11. GSK plc.
• 13.12. Bristol-Myers Squibb Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer